pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 1·1 min read
save

Researchers claim creation of first fully synthetic cell, launch public benefit corporation to share technology

Jul 1, 2026·read at STAT ↗Positive

Researchers at the University of Minnesota reported in a preprint that they have built what they call a synthetic cell, dubbed "SpudCell," which they suggest may be the first of its kind.

The team constructed tiny lipid bubbles, known as liposomes, and loaded them with circular DNA molecules called plasmids. These vesicles appear to replicate their DNA and divide, with about 30% of the bubbles still containing the original DNA after five generations.

To make the technology widely available, the scientists have formed a public benefit corporation aimed at sharing the methods with other labs. The work has sparked discussion about whether such engineered structures should be considered alive, highlighting both the promise and the unanswered questions in synthetic biology.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Synthetic biology researchers think they’ve made a cell. Is it alive?”

read at STAT ↗
528 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Minnesota2
topics
Cell TherapyHematologyOncology

related stories

  • Jun 30STAT+: FDA digital leader hints at coming AI policy updatesSTAT
  • Jun 3Legend surges on early data for ‘in vivo’ lymphoma cell therapyBioPharma Dive
  • Jun 2Fulcrum exploring a potential sale after FDA sidelined its sickle cell drugBioPharma Dive
  • May 29Allogene CEO to step down; Agios drug fails key testBioPharma Dive
  • May 13FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLonclive